Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.17
Views: 1125

Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA

Dr Jennifer Litton speaks with ecancer at SABCS 2017 about the EMBRACA trial of talazoparib vs physicians choice for patients with mBRCA1 breast cancer.

With some patients still receiving treatment, Dr Litton reports on the improvements in both survival and quality of life for patients receiving talazoparib, noting a manageable toxicity profile with a slight risk of grade 1 alopecia. 

She outlines further trials of talazoparib, and considers the future of PARP inhibitors in breast cancer treatment.

Read the news story for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation